Aplastic Anemia Clinical Trials 2026 — Find Recruiting Studies

About Aplastic Anemia

Aplastic anemia is a life-threatening bone marrow failure syndrome characterized by pancytopenia resulting from destruction or suppression of hematopoietic stem cells, most commonly by autoreactive T lymphocytes. The acquired form is typically immune-mediated and may be triggered by viral infections, toxic exposures, or medications, though most cases are idiopathic. Treatment ranges from immunosuppressive therapy with antithymocyte globulin and cyclosporine to allogeneic hematopoietic stem cell transplantation in eligible patients.

Common Clinical Features

Severe fatigue and pallor from anemia Increased susceptibility to infections from neutropenia Easy bruising and bleeding from thrombocytopenia Petechiae and mucosal bleeding Shortness of breath with minimal exertion Recurrent infections including bacterial and fungal Bone marrow biopsy showing hypocellular marrow with fat replacement Absence of organomegaly or lymphadenopathy (differentiating from leukemia)

Clinical Trial Eligibility Tips

What to know before applying to Aplastic Anemia trials.

Severity classification (moderate, severe, or very severe AA based on neutrophil, platelet, and reticulocyte counts) determines trial eligibility; obtain a recent complete blood count and bone marrow biopsy report.

Prior immunosuppressive therapy history (IST) including ATG cycles, cyclosporine use, and response status is critical as most trials stratify by treatment-naive versus relapsed/refractory status.

Rule out inherited bone marrow failure syndromes (Fanconi anemia, dyskeratosis congenita) before trial enrollment, as many trials exclude these; telomere length testing and chromosome fragility assays may be required.